RLD 2203
Alternative Names: RLD-2203Latest Information Update: 03 Nov 2022
Price :
$50 *
At a glance
- Originator Hanmi Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 21 Sep 2022 Hanmi Pharmaceutical plans a phase I trial for Healthy volunteers in South Korea in November 2022(NCT05548543)
- 02 Aug 2022 Preclinical trials in Unspecified indication(s) in South Korea (unspecified route) before August 2022
- 02 Aug 2022 Hanmi Pharmaceutical plans a phase I trial (In volunteers) in South Korea (NCT05481307)